Content continues after advertisement

Therapeutics Research Note: Imepitoin Trial

Clinician's Brief (Capsule)

Neurology

|July 2016

Sign in to Print/View PDF

Imepitoin is a GABA-mimetic drug previously shown to have anticonvulsive activity in a canine seizure model. In this multicenter randomized trial, efficacy of imepitoin was comparable to phenobarbital in 226 client-owned dogs newly diagnosed with epilepsy. Adverse events (eg, sedation, polydipsia, increased appetite) were more common with phenobarbital than with imepitoin, and elevation in liver enzymes occurred only in the phenobarbital group. Safety of imepitoin was further evaluated in healthy beagles. Infrequent mild clinical signs of toxicity occurred at doses of 150 mg/kg twice a day; the no observable effect level (NOEL) was 90 mg/kg twice a day, which is 3× the recommended therapeutic dose. The authors concluded that imepitoin is safe and effective for treating canine epilepsy.

References

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Podcasts

Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy